Axel Nelson - Publications

Nodal localisation with magnetic seed in patients with stage III melanoma receiving neoadjuvant immune checkpoint inhibitors, a feasibility study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: April 20, 2026

Selecting Representative Tumour Bed Slices May Allow Reduced Embedding Without Loss of Accuracy in Response Evaluation to Neoadjuvant Immunotherapy in Stage IIIB/C Cutaneous Melanoma.

Journal: Cancers

Published: April 01, 2026

Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 24, 2026

Neoadjuvant immunotherapy for resectable cutaneous melanoma: a nationwide population-based cohort.

Journal: Journal of the National Cancer Institute

Published: March 11, 2026

Phase I trial of locoregional administration of autologous tumor-infiltrating lymphocytes in patients with uveal melanoma and liver metastases (the HAITILS trial).

Journal: Journal for immunotherapy of cancer

Published: February 10, 2026

Neoadjuvant Immunotherapy Using PD-1 Inhibitors for Resectable Stage III Cutaneous Melanoma-Different Outcomes Between Patients With Lymph Node and In-transit Metastases.

Journal: Annals of surgery

Published: February 06, 2026

Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab.

Journal: Immuno-oncology technology

Published: December 09, 2025

Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma - A Swedish retrospective real-world study (NEO-MEL).

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 25, 2025

A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial).

Journal: ESMO open

Published: March 21, 2024

Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUM.

Journal: Annals of surgery

Published: February 29, 2024

Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 20, 2023

Circulating syndecans during critical illness.

Journal: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

Published: November 09, 2016